Kyle D. Kuvalanka - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
Chief Financial Officer
Signature
/s/ Kyle D. Kuvalanka
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 21:19:44 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kuvalanka Kyle D. Chief Financial Officer C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Kyle D. Kuvalanka 08 Jan 2026 0001638904

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 370,423 $11.46 Direct F1
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 131,426 $18.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option shall vest on November 3, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F2 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney